Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026
GlobeNewsWire8/12/2026Neutral
ABUS
Arbutus Biopharma CorpNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$923.95M
P/E Ratio
5.91
EPS
$0.79
Beta
0.60
52W High
$5.38
52W Low
$3.44
50-Day MA
$4.54
200-Day MA
$4.46
Dividend Yield
—
Profit Margin
84.20%
Forward P/E
10.25
PEG Ratio
0.00
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania.
Fundamentals
| Revenue (TTM) | $181.72M |
| Gross Profit (TTM) | $163.92M |
| EBITDA | $147.47M |
| Operating Margin | -567.00% |
| Return on Equity | 89.60% |
| Return on Assets | 48.80% |
| Revenue/Share (TTM) | $0.94 |
| Book Value | $1.31 |
| Price-to-Book | 3.57 |
| Price-to-Sales (TTM) | 5.08 |
| EV/Revenue | 4.578 |
| EV/EBITDA | 5.43 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -90.60% |
| Shares Outstanding | $197.85M |
| Float | $122.66M |
| % Insiders | 20.43% |
| % Institutions | 72.32% |
Historical Volatility
HV 10-Day
30.71%
HV 20-Day
35.44%
HV 30-Day
43.20%
HV 60-Day
40.63%
HV Rank
36.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($5.53 target)
1
BuyLatest News
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech
GlobeNewsWire7/16/2026Neutral
Arbutus Biopharma: Moderna Validates My IP Bull Case
Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patents. As for ABUS' in-house assets, I think Imdusiran has shown durable viral control. The main caveat is that it comes from combo therapies. Their balance sheet gives them a comfortable runway to pursue imdusiran's upcoming Phase 2b trial, which is yet another optionality vertical for the stock.
Seeking Alpha7/13/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ABUS and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026